Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Assets (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Non-Current Assets for 15 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 17.79% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, down 41.9% year-over-year, with the annual reading at $1.8 million for FY2025, 17.79% down from the prior year.
  • Non-Current Assets hit $1.8 million in Q4 2025 for Cardiff Oncology, down from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.9 million in Q4 2022 to a low of $863000.0 in Q2 2021.
  • Historically, Non-Current Assets has averaged $3.2 million across 5 years, with a median of $3.6 million in 2021.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 345.77% in 2022 and later plummeted 49.44% in 2024.
  • Year by year, Non-Current Assets stood at $3.4 million in 2021, then skyrocketed by 43.61% to $4.9 million in 2022, then dropped by 13.9% to $4.2 million in 2023, then tumbled by 49.44% to $2.1 million in 2024, then decreased by 17.79% to $1.8 million in 2025.
  • Business Quant data shows Non-Current Assets for CRDF at $1.8 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.